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Background: Preventative inhaled treatments in cystic fibrosis will only be effective in 
maintaining lung health if used appropriately. An accurate adherence index should therefore 
reflect treatment effectiveness, but the standard method of reporting adherence, that is, as a 
percentage of the agreed regimen between clinicians and people with cystic fibrosis, does not 
account for the appropriateness of the treatment regimen. We describe two different indices of 
inhaled therapy adherence for adults with cystic fibrosis which take into account effectiveness, 
that is, “simple” and “sophisticated” normative adherence.
Methods to calculate normative adherence: Denominator adjustment involves fixing a 
minimum appropriate value based on the recommended therapy given a person’s characteristics. 
For simple normative adherence, the denominator is determined by the person’s Pseudomonas 
status. For sophisticated normative adherence, the denominator is determined by the person’s 
Pseudomonas status and history of pulmonary exacerbations over the previous year. Numerator 
adjustment involves capping the daily maximum inhaled therapy use at 100% so that medication 
overuse does not artificially inflate the adherence level.
Three illustrative cases: Case A is an example of inhaled therapy under prescription based 
on Pseudomonas status resulting in lower simple normative adherence compared to unadjusted 
adherence. Case B is an example of inhaled therapy under-prescription based on previous exac-
erbation history resulting in lower sophisticated normative adherence compared to unadjusted 
adherence and simple normative adherence. Case C is an example of nebulizer overuse exag-
gerating the magnitude of unadjusted adherence.
Conclusion: Different methods of reporting adherence can result in different magnitudes of 
adherence. We have proposed two methods of standardizing the calculation of adherence which 
should better reflect treatment effectiveness. The value of these indices can be tested empirically 
in clinical trials in which there is careful definition of treatment regimens related to key patient 
characteristics, alongside accurate measurement of health outcomes.
Keywords: cystic fibrosis, medication adherence, nebulizers and vaporizers, epidemiologic 
methods
Introduction
Cystic fibrosis (CF) is a multisystem genetic condition due to CF transmembrane 
conductance regulator protein dysfunction resulting in abnormal ion transport across 
epithelial cells.1 It is a progressive and life-limiting condition, characterized by 
recurrent lower respiratory tract infection leading to lung damage and death from 
respiratory failure.1 Life expectancy has nonetheless been improving with median 
survival now exceeding 37 years,2–4 largely due to the increasing availability of 
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effective therapy.5 Given the respiratory burden of CF, 
inhaled medications consisting of antibiotics and mucolyt-
ics are the main-stay therapies with multiple randomized 
controlled trials (RCTs) demonstrating the effectiveness 
of these treatments.6,7 However, effective therapy will only 
work if it is being used appropriately. Various studies have 
shown that in contrast to adherence rates within RCTs, 
which typically exceed 80%,8,9 median medication adher-
ence in clinical practice ranges between 30% and 50%.10–12 
With median adherence below 50% in adults, adherence 
is an important potential cause of treatment failure,13 and 
medication adherence rates are likely to be an important 
indicator of the quality of care.
The first step toward using adherence rate as an indicator 
of the quality of care is to measure it accurately. There is clear 
evidence that electronic data capture of medication adherence 
is superior in terms of accuracy compared with self-report or 
other indirect measures, such as pharmacy refill data.10,11,14 In 
CF, tamper-proof nebulizer systems which provide date- and 
time-stamped data for nebulized medication delivered are 
now available.15,16 These data logging nebulizers provide rich 
data that can potentially be used to support adherence15 with 
meta-analysis suggesting that feeding back data to patients 
can increase adherence by around 20%.17 In addition, adher-
ence data are crucial to clinical decision making.18 There 
is little point in responding to increased exacerbations and 
lung function decline by switching patients from twice daily 
tobramycin to thrice daily aztreonam lysine if the cause of 
exacerbations is untreated CF due to nonadherence. Where 
it is practical to do so, electronic data capture should be 
integrated into routine care and used as a “gold standard” 
measure of medication adherence.
Although CF is the most common life-limiting genetic 
condition in the UK, it is still relatively uncommon with a 
population of just over 10,000 people in the UK and 70,000 
worldwide.19 The UK CF registry data from 2014 document 
that only two out of the 60 UK specialist CF centers (28 
adult centers, 32 pediatric centers) have .400 patients.20 In 
a seminal paper in 1995, Mant and Hicks21 demonstrated that 
measuring processes of care proven in RCTs to reduce death 
could detect meaningful differences in care quality for myo-
cardial infarction with just 75 cases compared to 8,179 cases 
needed if mortality was used instead as the quality indicator. 
The relative utility of process and outcome measures in 
detecting variations in quality of care is particularly relevant 
to CF. In CF, a small patient population is spread across 
many hospital units so that outcome measures, such as lung 
function, will be relatively insensitive in detecting differences 
in quality of care between units whereas process measures, 
such as adherence, have the potential to more easily identify 
important variations in the quality of care.21
Terminology: defining adherence
There is a lack of consensus on the methods to report 
adherence. Adherence is typically reported as the total num-
ber of doses taken as a percentage of the target number of 
doses agreed between clinicians and patients.22 Percentage 
adherence clearly depends both on the numerator (ie, the 
actual number of doses taken) and denominator (ie, the tar-
get number of doses to be taken). An increase in percentage 
adherence (which intuitively might be expected to imply 
more effective treatment) could be due to increase in the 
number of doses taken, that is, an increase in the numerator 
(likely to represent an improvement in effectiveness) or a 
decrease in the target number of doses to be taken each day, 
that is, a decrease in the denominator (likely to represent a 
decrease in effectiveness).
In defining adherence, we have adopted and extended 
the approach used by Horne et al22 in the 2005 National 
Coordinating Centre for the Service Delivery and Organi-
sation report that considers the definitions of compliance, 
concordance, and adherence as terms to explore patients’ 
engagement with therapy.
Compliance is defined as “the extent to which the patient’s 
behavior matches the prescriber’s recommendations.”22 This 
term is used less often nowadays since it is taken to imply 
a paternalistic lack of collaboration in setting treatment 
goals.22 Concordance is used in various ways and is some-
times used incorrectly as a synonym for adherence.22 We use 
concordance to describe the agreement about the intended 
treatment regimen that the patient and clinician achieve after 
a shared discussion. Adherence is the metric that describes 
the amount of treatment that is taken once the target has been 
set through the process of discussion that enables the clini-
cian and patient to achieve concordance.22 In using the term 
“adherence” in this way, we acknowledge that the process of 
reaching concordance is essential to setting the target which 
will be the denominator of the adherence metric.
A definition of adherence that recognizes the important 
role of the denominator naturally leads to the need to signpost 
the decisions made about the denominator when an adher-
ence rate is described. Simply quoting that the patient has an 
adherence rate of 50% without qualifying the denominator 
is uninformative. It therefore makes sense to use terminol-
ogy to describe adherence that gives information about the 
target treatment regimen (denominator) that has been agreed 
between the patient and clinician. We thus use the term 
“normative adherence” to indicate that the target treatment 
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agreed between patient and clinician has taken account of 
evidence that indicates that the regimen should be effective. 
Thus, normative regimens lead to an adherence metric where 
the denominator is chosen on the basis of effectiveness. 
It should be acknowledged that the evidence that defines 
effective treatment regimens can be limited and the authority 
of the normative label can only be as good as the evidence 
that is available. In proposing the two working definitions 
of normative adherence (“simple” and “sophisticated” nor-
mative adherence), we have proposed definitions that will 
allow and require empirical testing. The proposition that the 
adherence definition is normative because it is associated 
with the outcomes the therapy is reported to achieve can 
be investigated empirically in data sets where adherence is 
carefully defined and key outcomes are measured.
When concordance around treatment goals is informed 
by considerations other than treatment effectiveness (eg, a 
regimen based on what adults with CF feel they can realis-
tically manage), we must acknowledge that the adherence 
target has not been driven primarily by evidence of pharma-
cological effectiveness – we therefore call this adherence 
“unadjusted”.
Thus, we can see that whereas normative adherence 
might be used as a process measure linked to outcomes 
demonstrated in RCTs and therefore have potential as a 
quality indicator; the unadjusted adherence has less value 
in this regard. Studies have shown that despite clear guide-
lines, only around two-thirds of the people with CF were 
prescribed the maintenance inhaled therapy recommended 
by guidelines.23–26 Given this variation in prescribing, simply 
measuring adherence to a treatment regimen without any 
assessment of the appropriateness of the regimen gives only 
a limited indication of the quality of care.
Treatment burden is often cited as a cause for poor adher-
ence among people with CF27 and treatment rationalization 
(eg, dropping inhaled mucolytic to reduce treatment burden) 
is often employed as a strategy to improve adherence.28 
Rationalizing treatment would reduce the target number of 
doses to be taken (ie, the denominator) and inflate unad-
justed adherence, yet reduce the effectiveness of a treatment 
regimen. In this case, an increase in measured adherence does 
not represent optimal therapeutic effectiveness. Adults with 
CF who are colonized with Pseudomonas will typically be 
prescribed at least twice daily nebulized antibiotics in addi-
tion to once daily nebulized mucolytic.29 If that person has 
been struggling to take even one nebulizer per day, the clini-
cal team may feel that temporarily simplifying the regimen 
with the aim of taking just one nebulizer per day might help 
that person build habit and confidence. However, a reduction 
in the agreed prescription from three nebulizers per day 
(ie, antibiotics and mucolytic) to just one nebulizer per day 
(ie, mucolytic only) would increase the unadjusted percentage 
adherence threefold without necessarily being accompanied 
by improvement in clinical outcomes, such as reduction in 
exacerbation frequency or stabilization of lung function.
We therefore propose that medication adherence among 
people with CF should be reported in a standardized way to 
allow appropriate interpretation of the adherence data. This 
approach also has the potential to lay the groundwork for the 
comparison of specialist CF center performance using the 
critical process measure of medication adherence.
In this paper, we aim to explore two different indices of 
inhaled therapy adherence for adults with CF, that is, simple 
and sophisticated normative adherence, and provide real-life 
examples of the change in adherence magnitude depending 
on how adherence is being reported. We focus on inhaled 
therapy because accurate adherence measurement with elec-
tronic data capture is now technically possible and could be 
made routinely available. In extending our understanding 
of adherence, we have used patient characteristics that are 
routinely available in both the UK and US CF registries with 
the advantage that adherence indicators might be more eas-
ily incorporated into these national data sets. In this paper, 
we have simplified our task to some extent by choosing to 
concentrate on developing adherence indices that only apply 
to adults (defined as age 16 years or above) because the 
normative treatment in CF differs slightly between adults 
and children.
Methods to standardize the 
reporting of medication adherence
A crucial aspect of standardizing the reporting of inhaled 
therapy adherence is to fix the minimum denominator at an 
appropriate value based on the recommended therapy given a 
person with CF characteristics. In this way, we aim to define the 
normative treatment regimen by linking the person’s charac-
teristics to consensus guidelines. While there is currently little 
empirical evidence relating composite regimens to outcomes, 
trials in which there is careful definition of nebulizer regimens 
related to key patient characteristics alongside accurate mea-
surement of outcomes, such as exacerbations, will have the 
potential to provide data linking regimens to outcomes.
Simple normative adherence: adjusting 
the denominator according to 
Pseudomonas status
In adults, recommended inhaled therapy regimens will almost 
always include a mucolytic and then further drug choice will 
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be informed by the person’s Pseudomonas status. Dornase 
alfa is the mucolytic with the strongest evidence base for 
people with CF.6 It should be noted that while comparative 
effectiveness research is still rare in CF,30 the small number of 
trials comparing dornase alfa against alternative mucolytics 
(such as hypertonic saline and mannitol) failed to demonstrate 
the superiority of these alternatives.31–33 The US CF Founda-
tion recommends long-term dornase alfa for people with CF 
and at least mild lung disease, defined as predicted forced 
expiratory volume in 1 second (FEV
1
) of 90% or below,29 
while the European CF Society recommends the routine 
long-term use of dornase alfa for everyone with CF aged 
6 years and above.34 There is some evidence that dornase 
alfa reduces the frequency of pulmonary exacerbation even 
among those with normal FEV
1
.35–37 It is therefore justifiable 
for every adult with CF to be on long-term inhaled dornase 
alfa, which is given once daily.
People with CF have accelerated lung function decline 
once they are chronically colonized with Pseudomonas.38 
There is evidence that the decline can be reduced by 
long-term inhaled antibiotics.7,39,40 Colistimethate sodium 
and tobramycin are the two most commonly used antibiotics 
to suppress chronic Pseudomonas, while aztreonam lysine 
is a new treatment available since 2012.41 All the main CF 
guidelines recommend the use of long-term inhaled anti-
biotics if a person with CF is chronically colonized with 
Pseudomonas.29,42
Therefore, the Pseudomonas status of an adult with CF 
provides a basis to determine his/her minimum required 
treatment. An adult with CF should be on at least one 
inhaled therapy per day (ie, inhaled dornase alfa). If there is 
evidence of chronic Pseudomonas colonization, then he or 
she should be on a minimum of three inhaled therapies per 
day long-term (ie, once daily inhaled dornase alfa and twice 
daily inhaled antibiotic).
Once this has been defined, further adjustment can be 
made to take account of intermittent inhaled antibiotic 
regimens.43 For example, inhaled tobramycin and inhaled 
aztreonam lysine are usually prescribed on a 28-day on/off 
cycles.29 For people with chronic Pseudomonas whose regi-
men consists of only one type of intermittent inhaled antibiot-
ics, their minimum denominator would be 3 during the 28-day 
“on” period and 1 during the 28-day “off” period.
It should also be noted that in some CF centers, inhaled 
therapy is discontinued during treatment with intravenous 
antibiotics. In such centers, periods of intravenous therapy 
need to be excluded from the adherence calculations to take 
into account agreed missed doses.
Intermittent Pseudomonas
Further regimen adjustments are needed for those with inter-
mittent Pseudomonas. There is strong evidence that early 
inhaled therapy following the first isolation of Pseudomo-
nas can successfully eradicate Pseudomonas among people 
with CF.44 Latest evidence suggests the success rates of 
Pseudomonas eradication are similar between children and 
adults.45,46 All the main CF guidelines strongly recommend 
Pseudomonas eradication,34,42,47 although there is a lack of 
consensus regarding the eradication regimen. The US CF 
Foundation recommends 1 month of twice daily tobramycin 
as the first-line treatment47 while the UK CF Trust recom-
mends 3 months of colistimethate sodium.42 Therefore, 
when persons with CF who had been clear of Pseudomonas 
reacquire Pseudomonas, they should be treated with twice 
daily inhaled antibiotics for 1 or 3 months depending on the 
antibiotic regimen chosen (ie, a minimum of three inhaled 
therapies per day for 1 or 3 months depending on the anti-
biotic regimen during the eradication period, then back to 
one inhaled therapy).
How can normative adherence be used 
to understand quality of care across CF 
units?
Clinical medicine is inherently complex and in many cases 
progress can only be made if we do not allow the perfect to 
be the enemy of the good. Improvement in quality of care is 
supported by measurement that allows feedback to prompt 
improvement and subsequent reassessment.48 A CF unit with 
normative adherence of 30% might well learn from a unit 
with normative adherence of 60%, but benchmarking using 
normative adherence will require units to have confidence 
that apples are being compared to apples and not to oranges. 
Whereas understanding adherence data for patients with 
intermittent Pseudomonas is inherently complex, there is 
broad consensus around treatment for chronic Pseudomonas. 
The 2014 UK CF registry report suggests that nearly 50% of 
adults with CF are chronically colonized with Pseudomonas20 
and normative adherence for this group will allow important 
comparisons on a significant proportion of the adults with 
CF in a specialist CF center.
Initial steps toward a longer term goal
It is important to note that the initial emphasis in understanding 
normative adherence among people with CF, such as those 
with chronic Pseudomonas, is to define a minimum denomi-
nator value that will allow broad comparison across rela-
tively homogenous groups of people, rather than mandating 
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a denominator that will apply to every person with CF. This 
is an approach in which the perfect is not allowed to be the 
enemy of the good and in which starting to measure adher-
ence in a standardized way provides the first step in a longer 
journey of beginning to understand how much treatment is 
adequate for an individual with CF, depending on the severity 
of his/her lung disease. We recognize there is a wide range 
of lung disease severity and some people would require more 
than the minimum amount of treatment. For example, some-
one with chronic Pseudomonas might require (and agree to) 
regular twice daily colistimethate sodium, once daily dornase 
alfa, and twice daily hypertonic saline solution. In such an 
individual, the denominator should be 5 instead of 3. The 
data to achieve this level of precision in the personalization 
of adherence targets are not yet available. However, the 
eventual goal in understanding normative adherence should 
be to define the metric that identifies the level of treatment 
that will maintain stability and prevent exacerbations given 
an individual’s characteristics.
While dornase alfa and nebulized antibiotics are consid-
ered as the “core treatments” within CF, we recognize that 
other nebulized treatments, such as hypertonic saline and 
bronchodilators, are also used by people with CF. There may 
also be people with CF who just used hypertonic saline ± 
nebulized bronchodilators. Based on the definition of simple 
normative adherence whereby everyone should be on at least 
dornase alfa, this group of people will have an adherence of 
0% regardless of the number of hypertonic saline or nebulized 
bronchodilators used. Although this may seem unsatisfac-
tory, defining the minimum treatment denominator based 
only on the core treatments is a pragmatic decision to allow 
consideration of treatment regimen effectiveness.
Another issue would be the occasional (as needed) use of 
additional doses of hypertonic saline (or nebulized broncho-
dilator) over and above the core regimen of dornase alfa and 
inhaled antibiotics. In that case, a pragmatic decision can be 
made to decide that the core denominator remains at three 
doses per day and accept that it is impossible to be certain 
whether the three doses taken are the most important “norma-
tive” therapies. If there is regular use of hypertonic saline (or 
nebulized bronchodilator), then these therapies simply need 
to be included in the denominator as discussed earlier.
Unadjusted adherence as a potential 
quality indicator
It is important to recognize that center comparisons may 
sometimes need to use data that are not as complete as 
we would wish it to be. Some CF centers that struggle to 
deliver high quality care will also struggle to provide data 
sets with high levels of data completeness. This may well 
mean that a data capture system that uses chipped nebulizers 
may automatically provide data on how many total doses 
of nebulized therapy have been delivered, but the data that 
require unit level input, such as detailed prescription data or 
patient characteristics, may be missing.
It will be important to explore the potential of crude 
unadjusted adherence metrics to identify differences between 
centers since for some centers the data to allow normative 
adherence to be calculated may be missing. There are obser-
vational data from the US that relatively crude metrics can 
indicate differences in quality of care.49 The ESCF study 
showed that the centers with the best outcomes reviewed 
their patients more frequently than those that did not, 
and this analysis was only stratified according to FEV
1
.49 
Similarly, centers that used more intravenous antibiotics had 
better outcomes than those that used less. It may be that an 
unsophisticated comparison of unadjusted adherence that 
simply looks at the mean number of nebulized doses taken 
per patient per year may identify centers delivering different 
levels of quality of care. Such a metric will consider both 
the core treatments, such as dornase alfa, and also “add on 
treatments”, such as nebulized bronchodilators.
It is possible that data linkage between UK CF registry 
and automatic nebulizer download may allow some coarse 
adjustment, for example, for FEV
1
 as an indicator of lung 
disease severity. Although developing high quality metrics 
adjusted for known confounders is likely to develop the most 
discriminating and informative comparisons, more work is 
needed to understand what information can be gleaned from 
the data sets with missing data.
Sophisticated normative adherence: 
adjusting the denominator based on 
several prognostic factors
Sophisticated normative adherence is an exploratory 
approach that goes beyond the simple normative adherence 
by also taking into account exacerbation history from the 
previous 1 year (in the form of intravenous antibiotics used) 
to determine the need for inhaled antibiotics. This approach 
mirrors a published National Health Service (NHS) England 
guideline informed by the evidence from RCTs.50 The NHS 
England Clinical Commissioning Policy recommends that 
it would be appropriate to escalate to thrice daily aztreonam 
lysine for people with CF who are having more than two 
episodes of exacerbations annually or losing .2% of FEV
1
 
per year despite alternating regimen of nebulized tobramycin 
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and colistimethate sodium.50 Hence, exacerbation frequency 
is already being used to personalize normative adherence 
within the NHS England commissioning guidelines.
An understanding of the importance of exacerbation 
frequency in determining the choice of inhaled antibiotics 
may provide a helpful starting point in deciding treatment 
regimens for people with CF in whom Pseudomonas status 
is difficult to define. Although there are clear guidelines 
for diagnosing “chronic Pseudomonas” in people with 
CF,51,52 there are occasions whereby the diagnosis is less 
straightforward. Not everyone with CF is able to expecto-
rate sputum, and cough swabs have limited sensitivity in 
detecting Pseudomonas.53–55 Although anti-Pseudomonas 
antibody is useful in some cases, not every CF center has 
access to good quality and rapid anti-Pseudomonas antibody 
results.51 Intermediate values of anti-Pseudomonas antibody 
are also difficult to interpret.56 The Leeds definition (which 
does not rely on anti-Pseudomonas antibody levels51) 
remains the most commonly used method to determine the 
Pseudomonas status of a person with CF. However, with 
4,818 of the 39,326 participants in the observational ESCF 
study with indeterminate Pseudomonas status based on the 
Leeds definition,57 determining the requirement for inhaled 
antibiotics based on Pseudomonas status alone may be 
inadequate. There are people without Pseudomonas infec-
tion who still have frequent exacerbations,58,59 and there is a 
wide range of exacerbation frequency even among those with 
chronic Pseudomonas.60 A history of more than one previous 
exacerbation in the previous year is a strong risk factor for 
more frequent exacerbations.60–62 It could be argued that 
people with CF experiencing more frequent exacerbations 
and having higher intravenous antibiotics requirement would 
benefit from inhaled antibiotics. Thus, in people without 
confirmed evidence of chronic Pseudomonas who might 
otherwise simply be on an inhaled mucolytic, it could make 
sense to use a history of more than one previous exacerbation 
in the previous year as a reason to recommend the need for 
inhaled antibiotic therapy. Once adherence measurement is 
embedded within CF registries, the benefit of this approach 
can be investigated empirically.
The requirement for intravenous antibiotics has been 
used as a pragmatic marker for the frequency and sever-
ity of pulmonary exacerbations in various clinical trials 
and observational studies.63–69 Higher requirement for intra-
venous antibiotics is an independent predictor for higher 
mortality.63,64 Large observational studies showed a median 
number of exacerbations per year of around one among 
adults with CF,57,58 which corresponds with around 14 days 
of intravenous antibiotics.70 Therefore, a cutoff of 14 days 
in the past year is clinically reasonable to differentiate 
between those with “low” and “high” intravenous antibiotics 
requirement. According to the sophisticated normative adher-
ence index, someone with .14 days of intravenous antibiot-
ics use in the previous 1 year should be on once daily inhaled 
dornase alfa and twice daily inhaled antibiotic for the current 
year regardless of his or her Pseudomonas status.
Numerator adjustments
In defining simple and sophisticated normative adherence, we 
have attempted to produce a definition of adherence that might 
be expected to ensure that a higher percentage adherence to 
the specified regimen is associated with greater effectiveness 
(in terms of controlling inflammation, limiting exacerbations, 
and minimizing FEV
1
 decline) and a lower percentage adher-
ence associated with lower effectiveness. These normative 
adherence indices achieve this by adjusting the denominator 
(the drugs within the regimen) in the light of a person with 
CF’s clinical characteristics. However, just as the drugs within 
a regimen (the denominator) might be expected to influence 
effectiveness, the way in which the drugs are taken (the 
numerator) will also be important. Unless the influences of the 
numerator are understood, a measure of normative adherence 
may not accurately estimate regimen effectiveness.
The most important numerator adjustment is to 
cap the daily maximum inhaled therapy use at 100%. 
While “medication dumping” is difficult with I-neb® (Philips 
Respironics, MA, USA), which only emits aerosol on inspi-
ration, overuse of medication (ie, adherence .100%) at a 
certain period can inflate the unadjusted adherence figures 
without necessarily improving health outcomes. For example, 
after missing inhaled therapy over the weekend, a person 
may try to compensate by using more than the recommended 
doses of medication on Monday. Such a strategy might allow 
untreated inflammation to produce lung damage during 
“treatment holidays”. If this possibility is not accommodated 
within the definition of adherence that explores the impact of 
adherence on health outcomes, the magnitude of adherence 
may fail to detect the impact of inconsistent use.
By imposing a limit of 100% adherence per day 
(ie, excess nebulizer use is discounted), the calculated adher-
ence magnitude will better reflect the effective doses of 
medication used.
When calculating normative adherence by combining 
numerator and denominator adjustments, it is important 
to do the numerator adjustment first (so that maximum 
number of nebulizers used per day is no .100%) prior to 
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dividing the number of nebulizers used by the appropriate 
normative denominator. It is also important to note that the 
maximum number of nebulizers used per day is limited by 
the agreed prescription instead of the normative denominator. 
For example, if someone is only prescribed colistimethate 
sodium but needs colistimethate sodium and dornase alfa 
due to chronic Pseudomonas, even if the person used three 
colistimethate sodium doses per day, his/her maximum daily 
nebulizer use is still limited at two because the maximum 
recommended colistimethate sodium use is twice daily and 
the prescribed treatments do not include dornase alfa (which 
means that person does not possess the medications required 
to achieve 100% normative adherence).
The sophisticated normative adherence index can be 
further extended to take into account other technical factors 
that may influence treatment effectiveness, such as the need 
to use the I-neb twice to receive a full dose of nebulized 
tobramycin. These issues are discussed in the Supplementary 
materials.
Practical examples of adherence 
reported with the normative 
adherence indices
We present three composite cases which contain typical 
characteristics of people with CF based on our experience 
to provide practical examples of calculating the normative 
adherence indices. These cases are summarized in Table 1. 
These are illustrative rather than real cases.
Illustrative case A: under-prescription 
of inhaled therapy as defined by 
Pseudomonas status
Person A is in his mid-30s and has chronic Pseudomonas in 
2014 based on the Leeds definition.51 His best FEV
1
 in 2014 
was 116%. He did not require any intravenous antibiotics 
in 2013.
He was prescribed regular twice daily nebulized colis-
timethate sodium only. His dornase alfa was discontinued 
at his request in July 2011 because he struggled to use his 
inhaled therapy.
He used 203 nebulizers throughout 2014. His agreed 
prescription was twice daily nebulized colistimethate sodium, 
so his agreed target was 730 doses. Therefore, his unadjusted 
nebulizer adherence for 2014 was 203/(2×365) =27.8% of 
the agreed or prescribed doses.
According to the simple normative adherence index, 
his chronic Pseudomonas meant that his minimum inhaled 
therapy would be once daily inhaled mucolytic and twice 
daily inhaled antibiotic throughout 2014. Therefore, the 
denominator for calculating his adherence should have 
been 3 throughout 2014 (instead of 2). His simple norma-
tive adherence index for 2014 would therefore be 203/
(3×365) =18.5%.
His sophisticated normative adherence index for 2014 
is identical to his simple normative adherence because his 
Pseudomonas status means that he should be on both inhaled 
antibiotics and a mucolytic.
Table 1 Summary of the different adherence values depending on how the medication adherence is reported
Example Unadjusted 
adherence (%)
“Simple” 
normative 
adherence 
(without 
numerator 
adjustment) (%)
“Sophisticated” 
normative 
adherence 
(without 
numerator 
adjustment) (%)
“Simple” 
normative 
adherence with 
numerator 
adjustment (%)
“Sophisticated” 
normative 
adherence with 
numerator 
adjustment (%)
Reasons for 
discrepancy
Person A 27.8 18.5 18.5 18.5 18.5 Under-prescription of 
inhaled therapy based 
on Pseudomonas 
status
Person B 61.1 61.1 20.4 61.1 20.4 Under-prescription 
of inhaled therapy 
based on previous 
intravenous antibiotic 
requirement
Person C 64.5 64.5 64.5 58.2 58.2 Brief period of 
nebulizer overuse 
resulted in slightly 
exaggerated 
unadjusted adherence 
figure
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Numerator adjustment did not affect his normative 
adherence index because there was no inappropriate nebulizer 
use or nebulizer overuse. When calculating the normative 
adherence with both numerator and denominator adjust-
ments, it is important to do the numerator adjustment first to 
determine his maximum daily nebulizer use prior to divid-
ing that figure with the normative denominator (which was 
3 in this case due to chronic Pseudomonas). Although his 
normative denominator was 3, his maximum daily nebulizer 
use was limited at 2 because the maximum recommended 
colistimethate sodium use is twice daily. Person A did not use 
more than two nebulizers in a single day in 2014; hence, even 
with the numerator adjustment capping his daily maximum 
nebulizer use per day at two, his total normative numerator 
for 2014 remained at 203 doses. Therefore, his simple norma-
tive adherence with numerator adjustment for 2014 would 
still be 203/(3×365) =18.5%.
Illustrative case B: under-prescription of 
inhaled therapy based on intravenous 
antibiotic requirement
Person B is in her early 30s who has not cultured Pseudomo-
nas since 2011, but was mainly providing cough swabs. 
Her best FEV
1
 in 2014 was 64%. She required 42 days of 
intravenous antibiotic in 2013.
She was on dornase alfa once daily throughout 2014, 
whereby she used 223 nebulizers out of the 365 agreed doses. 
Therefore, her unadjusted nebulizer adherence for 2014 was 
61.1% of the agreed or prescribed doses. Her simple norma-
tive adherence without numerator adjustment for 2014 was 
also 61.1% because no denominator adjustment was needed 
given that she did not culture Pseudomonas in 2014.
Sophisticated normative adherence uses exacerbation 
frequency data as an indicator of untreated inflammation/
infection and escalates recommended treatment to respond 
to this. Based on her intravenous antibiotics requirement 
being .14 days in 2013, her sophisticated normative 
adherence would indicate that she required inhaled anti-
biotic throughout 2014. Her sophisticated normative 
adherence without numerator adjustment for 2014 would 
therefore be 20.4%, based on a denominator of 3 per day 
(instead of 1 per day).
Her normative adherence indices for 2014 remained 
identical following numerator adjustment (61.1% for simple 
normative adherence, 20.4% for sophisticated normative 
adherence) because there was no inappropriate nebulizer use 
or nebulizer overuse.
The difference between simple and sophisticated normative 
adherence is marked in this case and it should be noted that 
sophisticated normative adherence is an exploratory concept 
that will require empirical testing in clinical practice.
Illustrative case C: brief periods of 
nebulizer overuse resulted in a slightly 
exaggerated unadjusted adherence
Person C is in his mid-30s with chronic Pseudomonas in 
2014 based on the Leeds definition.51 His best FEV
1
 in 2014 
was 85% and he required 38 days of intravenous antibiotics 
in 2013.
Throughout 2014, he was on once daily dornase alfa 
and twice daily nebulized colistimethate sodium alternating 
every 2 weeks with twice daily nebulized tobramycin. It is 
important to note that he was taking his tobramycin through 
the I-neb, which requires two separate nebulizations to take 
a single full dose, so twice daily tobramycin requires four 
nebulizations.
He completed 848 nebulizer treatments throughout 2014. 
Of note, from October to November 2014, he was using 
dornase alfa twice daily.
Given that he was already prescribed both inhaled 
mucolytic and antibiotic (ie, no adjustments to the denomi-
nator are required to calculate his normative adherence), 
his unadjusted adherence and normative adherence without 
numerator adjustment (for both simple and sophisticated) 
were all identical at 64.5%.
However, with numerator adjustment, both his normative 
adherence indices would be slightly lower at 58.2% due to the 
capping of daily maximum adherence at 100%, which negates 
the effect of excess dornase alfa use. Following numerator 
adjustment limiting his maximum daily nebulizer use at 3 per 
day (in accordance with his agreed prescription of once daily 
dornase alfa and twice daily nebulized antibiotics), he only 
used 637 doses of effective nebulized treatments in 2014. 
Therefore, his normative adherence with both denominator 
and numerator adjustments would be 637/(3×365) =58.2%.
Discussion
We have described the principles of adjusting adherence 
data to standardize the reporting of adherence rates using an 
approach that links reported adherence rates to evidence on 
effectiveness. The aim is to make adherence rates easier to 
interpret and allow comparison of quality of care. The most 
important aspect of simple normative adherence is to set a 
minimum value for treatment, which defines the denominator 
of the adherence rate based on the inhaled therapy targets 
for a given person with CF. These targets are derived from 
consensus guidelines informed by RCTs.34,42,47 Adjusting the 
numerator potentially adds further useful information and 
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provides a more accurate reflection of how inhaled therapy 
is being used by people with CF by capping the daily maxi-
mum adherence at 100%. We have also provided practical 
examples of the common scenarios, whereby adherence 
magnitude may change depending on how it is reported.
The term normative was first used in the context of medi-
cation adherence in the National Coordinating Centre for the 
Service Delivery and Organisation report by Horne et al.22 
In this report, normative was used to represent “good” and 
“right” medication taking. We used the term normative 
adherence to describe adjusted adherence indices based on 
the right regimen, whereby the right medication regimen is 
the regimen that the evidence suggests will be effective in 
delivering the outcomes that the medication is prescribed to 
achieve according to the RCT evidence. Typical outcomes 
the medication is “advertised” to deliver will be reduction in 
pulmonary exacerbations or improvement in lung function. 
Hence, normative adherence indices are more than just adher-
ence (described as the extent to which a patient’s behavior 
matches an agreed treatment plan)22 in that normative adher-
ence takes into account whether the agreed treatment is likely 
to be the optimum regimen for a person with CF given his/
her characteristics. In this way, the normative adherence rate 
evaluates the prescribing practices of health care profession-
als as well as medication use by people with CF.
The approach we have taken in CF is similar to the approach 
of the Global Initiative for Chronic Obstructive Lung Disease 
guideline in recommending COPD treatments.71 While we 
have started with the CF clinical guidelines that recommend 
treatments on the basis of some patient characteristics,29,34,42 
in developing the sophisticated normative adherence 
index, we have extended the patient characterization to include 
a proxy for exacerbations that is available for all UK and US 
patients in the form of annual intravenous days within the 
national CF registries. This paves the way for quality assess-
ment across registry data using the well-characterized process 
measure of normative adherence.
We have presented two different methods of calculating 
normative adherence. Accurate medication adherence 
measures should predict health outcomes.72 We think it is 
likely that adjusting the denominator according to a person’s 
Pseudomonas status ± history of exacerbation in the previ-
ous 1 year along with capping the daily maximum inhaled 
therapy use at 100% should improve the accuracy of an adher-
ence index in predicting health outcomes. The relationship 
between normative adherence and health outcomes, such as 
intravenous days, should be testable within registry data once 
adherence measures become embedded in clinical care. The 
technology to allow this is available and starting to become 
increasingly used.18 An appropriate data set to compare the 
predictive values of different normative adherence defini-
tions would be an adequately powered RCT of adherence 
intervention among people with CF. Such a trial has been 
funded by the National Institute of Health Research and the 
pilot phase will begin in May 2016.73
There are additional potential adjustments to both the 
numerator and denominator that could be made to further 
improve the accuracy of the normative adherence index, and 
these are discussed in the Supplementary materials.
Normative adherence can be viewed as another dimension 
of personalized medicine.74 Developing a detailed under-
standing of an individual’s normative adherence holds out 
the promise of defining the minimum amount of adherence 
required for maintaining optimal lung health. Given the 
increasing treatment options in CF,75 understanding “how 
much adherence is enough” will be vital in helping to tackle 
the increasing CF treatment complexity.76
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Supplementary materials
Further considerations in calculating the 
“sophisticated” normative adherence 
index
extending sophisticated normative adherence: 
further considerations for the denominator 
adjustment
The precision of the “sophisticated” adherence index might 
be increased by also taking into account lung function and 
the severity of the underlying cystic fibrosis (CF) by con-
sidering genotype and pancreatic status. For convenience, 
we will call this index “extended sophisticated” normative 
adherence. Whether the additional complexity is of value 
can potentially be tested empirically and care has been 
taken to only select adjustment factors that are available in 
the national CF registries to make such empirical testing 
feasible in the future.
The additional factors involved in the extended sophis-
ticated normative adherence would allow the index to be 
sufficiently discriminating to provide guidance as to whether 
a given adult with CF would require dornase alfa rather 
than simply assuming that all adults with CF should be pre-
scribed dornase alfa. This has particular relevance because 
widespread genetic testing is identifying rarer cystic fibrosis 
transmembrane conductance regulator (CFTR) mutations, 
leading to CF centers providing care to an increasing popula-
tion of older and “atypical” cases that would otherwise not 
be diagnosed as CF.1 A small group of people with CF have 
very mild clinical manifestations and near normal lung func-
tion even at an sophisticated age.2–4 In this group of people, 
there is likely to be less of a consensus about the blanket use 
of inhaled mucolytic.
Thus, the extended sophisticated normative adherence 
would potentially identify a group of people who need not 
necessarily be on any inhaled therapy based on no evidence 
of Pseudomonas, no history of frequent exacerbations 
(with the requirement of .14 days of intravenous antibiot-
ics in 1 year as a marker of frequent exacerbation), forced 
expiratory volume in 1 second (FEV
1
) .90%, pancreatic 
sufficient, and “mild genotype” (at least one class IV–V 
CFTR mutation5).
FEV
1
 .90% is accepted by the US CF Foundation as 
“normal lung function”, whereby long-term dornase alfa 
is not considered essential.6 Pancreatic insufficiency is an 
independent risk factor for increased FEV
1
 decline among 
people with CF7–9 and is associated with poorer prognosis.1 
A potential disadvantage of relying solely on the pancreatic 
status to identify milder phenotype is that people with mild 
phenotype who were initially pancreatic sufficient may even-
tually become pancreatic insufficient after a series of episodes 
of pancreatitis.10 Although there is significant phenotypic 
variability for each class of CFTR mutation, the relation-
ship between pancreatic status and genotype is more robust 
and the group with at least one class IV–V CFTR mutation 
does tend to have milder lung disease.2,5,11,12 Therefore, the 
genotype is useful in supplementing the information provided 
by pancreatic status in terms of confirming that an individual 
has a milder phenotype.
Figure S1 summarizes the rubric for combining the 
different prognostic factors used to determine the required 
maintenance inhaled therapy for this form of sophisticated 
normative adherence index.
taking into account incomplete doses: numerator 
adjustment for adherence levels calculated from 
I-neb® data
The I-neb® records four different readings for each nebulizer 
dose depending on treatment completeness: “full” = full 
nebulizer dose delivered; “12.5%–100%” = treatment taken 
but incomplete dose; “,12.5%” = treatment attempted but 
unlikely to receive any; and “none” = I-neb® switched on but 
no treatment taken.13 To ensure that the number of treatments 
is correctly calculated, a ”full” dose is counted as “1 dose”, 
“12.5%–100%” is counted as “½ dose” while “,12.5%” and 
“none” doses are counted as 0.
taking into account doses taken after midnight: 
numerator adjustment for irregular lifestyles
When a limit of 100% adherence per day is being used as part 
of numerator adjustment, it can be informative to recognize 
that many young people will go to bed after midnight. It is 
not uncommon for these “night owls” to use their inhaled 
therapy after midnight (eg, after returning from a night out). 
For example, a person may use his inhaled antibiotic at 10 am 
and take the final dose of the day just before bed, which 
may on occasions be 1 or 2 am. Let us say the second lot of 
inhaled therapy (this time an inhaled antibiotic and inhaled 
dornase alfa) was used around 1 am the next morning. He/she 
woke up around 10 am to start his/her new day and used his/
her morning inhaled antibiotic. Finally, he/she used his/her 
second lot of inhaled therapy (inhaled antibiotic and inhaled 
dornase alfa) at around 11 pm. The unadjusted adherence 
over the 2 days would be 100% (six nebulizers used out of 
six prescribed). Capping the daily maximum at 100% using 
a rigid midnight-to-midnight day would result in one nebu-
lizer counted for the first day and three nebulizers counted 
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for the second day (ie, adherence over the 2 days would only 
be 67%). Counting a day as starting at 5 am and ending at 
4.59 am is a pragmatic solution to this problem, since it is 
likely that on most occasions a person would go to bed by 
5 am and would wake up for the day by 4 pm.14
Therefore, to prevent intermittent late doses pushing 
some days over 100% and leaving other days under 100%, 
which would lead to a lower overall adherence level due to 
capping the maximum daily inhaled therapy use at 100%, 
“a day” should be considered to start at 5 am.
taking into account dose spacing: numerator 
adjustment for inhaled antibiotics
Another factor that could be considered in ensuring that the 
adherence index most accurately reflects medication effec-
tiveness is to consider dose spacing.
The common inhaled antibiotic therapies (colistimethate 
sodium and tobramycin) in CF should be used twice daily, that 
is, every 12 hours, while inhaled aztreonam lysine dosing is 
thrice daily. Inhaled antibiotic doses used too close together may 
not be as beneficial as doses used at the recommended intervals. 
Figure S1 The required maintenance inhaled therapy based on a range of prognostic factors used to decide the minimum denominator for the “extended sophisticated” 
normative adherence.
Notes: ψPseudomonas status as defined by the Leeds definition.16 People with intermittent Pseudomonas should be on inhaled antibiotics in addition to inhaled mucolytic for 
1 month or 3 months depending on the antibiotic regime when Pseudomonas is newly detected. ΩGenotype status as defined by international consensus.5 “Mild genotype” is 
defined by the presence of at least one class IV–V CFTR mutation.
Abbreviations: CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume in 1 second; IV, intravenous.
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The UK CF Trust recommends a minimum interval of at least 
6 hours for inhaled colistimethate sodium and tobramycin.15 
Therefore, the numerator adjustment could exclude the inhaled 
antibiotic doses that were used ,6 hours after an initial dose.
taking into account device dose delivery 
characteristics: numerator adjustment for nebulized 
tobramycin via I-neb®
Nebulized tobramycin via the I-neb requires two separate 
nebulizations to complete a single dose due to the size of 
the chamber. Thus, the number of nebulizations per day will 
differ depending on whether the patient is on a mucolytic and 
tobramycin or mucolytic and colistimethate sodium. A person 
would take one nebulization for the dornase alfa and one 
nebulization for the colistimethate sodium in the morning 
and just one nebulization for the colistimethate sodium in the 
evening with a target of three nebulizations per day. If the 
patient was taking dornase alfa and tobramycin via the I-neb®, 
the morning nebulization target would be one nebulization for 
dornase alfa and the patient would need to use the nebulizer 
twice to deliver the full dose of tobramycin. Hence, the patient 
would have a target of five nebulizations per day.
A relatively common scenario is for people to use both an 
inhaled mucolytic and inhaled antibiotic within a “treatment 
session”, but miss their other inhaled antibiotic for the day. If 
the inhaled antibiotic is colistimethate sodium, the adherence 
would be 67% (two out of three nebulizers used). However, if 
the inhaled antibiotic is tobramycin solution, which requires 
two separate nebulizations for a complete dose via the I-neb, 
the adherence would only be 60% (three out of five nebuliz-
ers used). This discrepancy does not arise with other types of 
nebulizers, for example, the eFlow Rapid®, which does not 
require the tobramycin solution to be nebulized twice for a 
complete dose. Missing a dose of colistimethate sodium via 
the I-neb® should carry the same weight as missing a dose 
of tobramycin. Therefore, the numerator adjustment counts 
each nebulization of tobramycin solution via the I-neb® as “½ 
dose”, so that the complete dose (two nebulizations) would 
count as “1”. This allows the daily denominator to stay at 
“3” for those on both inhaled antibiotic and inhaled dornase 
alfa, thus avoiding the discrepancy between missing a dose of 
colistimethate sodium versus missing a dose of tobramycin.
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